Assenagon Asset Management S.A. Raises Holdings in AbbVie Inc. $ABBV

Assenagon Asset Management S.A. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 55.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 2,097,882 shares of the company’s stock after purchasing an additional 748,838 shares during the quarter. AbbVie accounts for about 0.7% of Assenagon Asset Management S.A.’s holdings, making the stock its 20th biggest holding. Assenagon Asset Management S.A.’s holdings in AbbVie were worth $527,911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABBV. Vanguard Group Inc. grew its position in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the last quarter. State Street Corp raised its holdings in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after buying an additional 356,394 shares during the period. Finally, Norges Bank acquired a new stake in shares of AbbVie during the fourth quarter worth $5,865,055,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

AbbVie Trading Down 1.0%

AbbVie stock opened at $243.64 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The stock’s 50 day simple moving average is $241.40 and its two-hundred day simple moving average is $224.82. The firm has a market cap of $430.46 billion, a PE ratio of 68.82, a P/E/G ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the company earned $2.97 EPS. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of several research reports. Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday. Bank of America lifted their price target on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Guggenheim raised their price objective on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $275.70.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.